TRA-1-60 - A NEW SERUM MARKER IN PATIENTS WITH GERM-CELL TUMORS

被引:15
|
作者
MARRINK, J
ANDREWS, PW
VANBRUMMEN, PJ
DEJONG, HJ
SLEIJFER, DT
KOOPS, HS
OOSTERHUIS, JW
机构
[1] WISTAR INST,PHILADELPHIA,PA 19104
[2] STATE UNIV GRONINGEN HOSP,DEPT MED ONCOL,9713 EZ GRONINGEN,NETHERLANDS
[3] STATE UNIV GRONINGEN HOSP,DEPT PATHOL,9713 EZ GRONINGEN,NETHERLANDS
[4] STATE UNIV GRONINGEN HOSP,DEPT SURG ONCOL,9713 EZ GRONINGEN,NETHERLANDS
关键词
D O I
10.1002/ijc.2910490309
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
TRA-1-60 is a monoclonal antibody (MAb) that recognizes a mucin-like antigenic determinant expressed on the surface of embryonal carcinoma (EC) progenitor cells. In order to determine whether this antigen is released into the serum of patients with a non-seminomatous germ-cell tumor (NSGCT), we developed a sensitive 2-step immunoenzymometric assay. Of 42 EC-positive NSGCT patients tested, 32 (76%) were found to release TRA-1-60-reactive antigen into their serum, in contrast to 1 positive finding in 10 EC-negative NSGCT patients. The marker was found in 67% (10/15) of the EC-positive patients who were negative for both AFP and HCG. Sera from seminoma patients did not contain elevated levels of the TRA-1-60 antigen. Therefore, we propose that the TRA-1-60 antigen is a useful additional serum marker for following the progress of NSGCT(EC+) patients.
引用
收藏
页码:368 / 372
页数:5
相关论文
共 50 条
  • [1] Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer
    Lajer, H
    Dauggard, G
    Andersson, AM
    Skakkebæk, NE
    INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (02) : 244 - 246
  • [2] IMMUNOHISTOCHEMICAL EXPRESSION OF EMBRYONAL MARKER TRA-1-60 IN CARCINOMA IN-SITU AND GERM-CELL TUMORS OF THE TESTIS
    GIWERCMAN, A
    ANDREWS, PW
    JORGENSEN, N
    MULLER, J
    GROEM, N
    SKAKKEBOEK, NE
    CANCER, 1993, 72 (04) : 1308 - 1314
  • [3] Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors
    Gels, ME
    Marrink, J
    Visser, P
    Sleijfer, DT
    Droste, JHJ
    Hoekstra, HJ
    Andrews, PW
    Koops, HS
    ANNALS OF SURGICAL ONCOLOGY, 1997, 4 (04) : 321 - 327
  • [4] Importance of a new tumor market TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors
    Mariël E. Gels
    Jan Marrink
    Petra Visser
    Dirk Th. Sleijfer
    Jos H. J. Droste
    Harald J. Hoekstra
    Peter W. Andrews
    Heimen Schraffordt Koops
    Annals of Surgical Oncology, 1997, 4 : 321 - 327
  • [5] FREQUENCY OF SERUM TUMOR-MARKER MONITORING IN PATIENTS WITH NONSEMINOTAMOUS GERM-CELL TUMORS
    SECKL, MJ
    RUSTIN, GJS
    BAGSHAWE, KD
    BRITISH JOURNAL OF CANCER, 1990, 61 (06) : 916 - 918
  • [6] SERUM FERRITIN AS A 3RD MARKER IN GERM-CELL TUMORS
    GRAIL, A
    BATES, G
    WARD, AM
    JONES, WG
    HANCOCK, BW
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (03): : 261 - 269
  • [7] SERUM FERRITIN AS A 3RD MARKER IN GERM-CELL TUMORS
    GRAIL, A
    BATES, G
    MILFORDWARD, A
    HANCOCK, BW
    BRITISH JOURNAL OF CANCER, 1981, 43 (05) : 726 - 726
  • [8] FREQUENCY OF SERUM TUMOR-MARKER MONITORING IN PATIENTS WITH NON-SEMINOMATOUS GERM-CELL TUMORS
    SECKL, MJ
    RUSTIN, GJS
    BAGSHAWE, KD
    BRITISH JOURNAL OF CANCER, 1989, 59 (05) : 822 - 823
  • [9] EXTRAGONADAL GERM-CELL TUMORS AND UNRECOGNIZED GERM-CELL TUMORS
    HAINSWORTH, JD
    GRECO, FA
    SEMINARS IN ONCOLOGY, 1992, 19 (02) : 119 - 127
  • [10] USEFULNESS OF SERUM LD-1 ISOENZYME IN PATIENTS WITH EXTRAGONADAL GERM-CELL TUMORS
    LIU, FJ
    FRITSCHE, HA
    TRUJILLO, JM
    SAMUELS, ML
    LOGOTHETIS, CJ
    TRINDADE, A
    CLINICAL CHEMISTRY, 1982, 28 (07) : 1560 - 1560